Abstract TMP110: The Correlation of Through Plasmatic Concentration of Dabigatran and CES1 Genotype With Major Bleeding in Stroke Patients

Stroke(2018)

Cited 2|Views11
No score
Abstract
Introduction: Dabigatran is direct thrombin inhibitor approved in the prevention of stroke in patients with atrial fibrillation. It was shown in the RELY trial substudy that genetic variants could contribute to interindividual variability in concentrations of the active metabolite of dabigatran and influence the safety of treatment. Carriage of the CES1 rs2244613 minor allele was associated with lower exposure to active metabolite and with a lower bleeding risk compared to wild-type allele. Aim: To determine the influence of gene CES1 polymorphism rs2244613 and through plasmatic concentration of dabigatran on occurrence of major bleeding in stroke patients. Methods: Prospective observational monocentric study in consenting stroke patients initiated on dabigatran. Primary outcome was major bleeding defined using ISTH criteria. DNA analysis of CES1 polymorphism rs2244613 was done with RFLP analysis. Through concentration of dabigatran was measured with liquid chromatography-tandem mass spectrometry (LC-MS/M...
More
Translated text
Key words
ces1 genotype,dabigatran,stroke,major bleeding,abstract tmp110
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined